PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history

Author： Degasperi Elisabetta Viganò Mauro Aghemo Alessio Lampertico Pietro Colombo Massimo

ISSN： 1478-7210

Source： Expert Review of Anti-Infective Therapy, Vol.11, Iss.5, 2013-05, pp. : 459-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Comparison of the Exponential Decay Slope between PEG-IFN alfa-2b/Ribavirin and IFN alfa-2b/Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Genotype 1b Infection and a High Viral Load

Intervirology, Vol. 47, Iss. 2, 2004-06 ,pp. : 102-107

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Pegylated Interferon-α_2a plus Ribavirin versus Pegylated Interferon-α_2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

Intervirology, Vol. 53, Iss. 3, 2010-01 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG‐interferon

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 318-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden

By Bernfort Lars Sennfält Karin Reichard Olle

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 6-7, 2006-07 ,pp. : 497-505

Informa Healthcare

Access to resources Recommend Favorite